Everest Medicines Ltd (HKSE:01952)
HK$ 39.1 4.8 (13.99%) Market Cap: 12.60 Bil Enterprise Value: 11.11 Bil PE Ratio: 0 PB Ratio: 2.65 GF Score: 41/100

Everest Medicines Ltd Business Update Conference Call Transcript

Aug 16, 2022 / 12:30AM GMT
Release Date Price: HK$13.64 (-19.10%)
Operator

Ladies and gentlemen, good day, and thank you for standing by. Welcome to Everest Medicines Transaction Announcement Conference Call. (Operator Instructions) Please be advised that the conference is being recorded.

I would now like to hand the conference over to your speaker today, Leah Liu, VP of Corporate Affairs. Please go ahead.

Leah Liu
Everest Medicines Limited - Joint Company Secretary

Thank you, operator. Good morning, everyone. Thank you for joining us today. We have announced this morning our agreement with Gilead on the regional rights of Trodelvy and would like to share more insights with you on this transaction on this call. Joining me today from the company are Dr. Kerry Blanchard, our CEO; and Mr. Ying Woo, our President and CFO.

Before we get started, I'd like to remind you that the speakers of this conference call may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the company or its officers with regards to the business operations and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot